Ana sayfa
Piyasalar
Grafikler ve fikirler
Algo
Haberler
Store
Aracı kurumlar
İndir
Ekonomik Takvim
Alım-satım sinyalleri
Web Terminali
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Türkçe
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
URGN
#2066
UroGen Pharma Ltd. Ordinary Shares
21.700
0
+4.28%
Sektör:
Baz:
Kar para birimi:
Günlük aralık
Yıllık aralık
Günlük değişim
+4.28%
Aylık değişim
-0.60%
6 aylık değişim
+14.21%
Yıllık değişim
+14.21%
Önceki kapanış
20.810
0
Open
21.700
0
Bid
Ask
Low
21.700
0
High
21.700
0
Hacim
74
Piyasalar
ABD hisse senetleri
Sağlık hizmetleri
URGN
Open full chart
Financials
Overview
Rapor
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
22.27 M
22.67 M
23.44 M
34.12 M
46.09 M
—
Valuation ratios
Enterprise value
348.49 M
171.21 M
147.12 M
423.99 M
318.92 M
2.11 B
Price to earnings ratio
—
—
1.79
4.29
3.6
16.97
Price to sales ratio
—
—
3.06
5.3
5.05
26.8
Price to cash flow ratio
—
—
2.25
5.74
4.72
21.28
Price to book ratio
—
—
2.21
6.73
51.87
63.46
Enterprise value to EBITDA ratio
-2.75
-1.87
-1.88
-6.55
-3.3
-17.73
Profitability ratios
Return on assets %
-1.05
-0.93
-0.81
-0.57
-0.44
-0.73
Return on equity %
-1.33
-13.17
-1.23
-1.57
-14.41
-6.03
Return on invested capital %
-1 235.54
-2 006.82
-1 488.99
-1 069.42
-1 457.96
-1 937.33
Gross margin %
91.45
89.27
88.11
88.68
90.18
351.85
Operating margin %
-1 074.15
-192.11
-122.82
-79.23
-107.06
-565.66
EBITDA margin %
-1 074.29
-190.44
-121.42
-78.27
-106.77
-568.25
Net margin %
-1 088.94
-230.67
-170.58
-123.61
-140.35
-696.75
Liquidity ratios
Quick ratio
5.3
4.9
5.21
5.24
5.81
19.06
Current ratio
5.39
5.11
5.39
5.42
6.01
19.79
Inventory turnover
—
—
0.19
0
—
—
Asset turnover
0.07
0.4
0.5
0.53
0.39
0.41
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
0.72
0.55
0.43
2.17
Long term debt to total equity ratio
—
—
-1.09
-1.51
-13.83
-18.83
Per share metrics
Operating cash flow per share
—
—
-3.84
-2.65
-2.26
-2.89
EBIT per share
—
—
-3.47
-2.27
-2.26
-2.82
EBITDA per share
—
—
-3.43
-2.25
-2.25
-2.82
Total debt per share
—
—
—
—
—
—
Cash per share
—
—
4.38
4.91
5.64
15.4
Net current asset value per share
—
—
5.65
5.87
6.44
18.5
Tangible book value per share
—
—
-3.92
-2.26
-0.21
-5.52
Working capital per share
—
—
4.6
4.79
5.37
14.77
Book value per share
—
—
-3.92
-2.26
-0.21
-5.52
Haberler
UroGen Pharma CMO’su Schoenberg 145 bin dolarlık hisse satışı gerçekleştirdi
UroGen Pharma CMO Schoenberg sells $145k in shares
enGene Holdings: A Potential Oncology Entrant (NASDAQ:ENGN)
2025 Performance Review And Future Strategy
Urogen Pharma Ltd hissesi 25,2 dolar ile 52 haftalık zirveye ulaştı
Urogen Pharma Ltd stock hits 52-week high at 25.2 USD
UroGen Pharma Guggenheim Konferansı’nda: UGN-102 Lansmanına İlişkin Stratejik Görüşler
UroGen Pharma at Guggenheim Conference: Strategic Insights into UGN-102 Launch
Urogen Pharma hisseleri 23,66 dolar ile 52 haftalık zirveye ulaştı
Urogen Pharma stock hits 52-week high at 23.66 USD
UroGen Pharma Ltd. (URGN) Q3 2025 Earnings Call Transcript
UroGen Pharma stock jumps after positive Phase 3 trial results